Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ioannis Drygiannakis

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Alimentary Pharmacology and Therapeutics

English

Immunological Alterations Mediated by Adenosine During Host-Microbial Interactions

Immunologic Research

Immunology

2011

English

Related publications

Pregnancy Outcomes in Women With Inflammatory Bowel Disease Treated With Biosimilar Infliximab

Gastroenterologie a Hepatologie

Hepatology

Gastroenterology

2018

English

Letter: Infliximab Therapy for Patients With Inflammatory Bowel Disease - Some Unanswered Questions. Authors’ Reply

Alimentary Pharmacology and Therapeutics

English

Switching Maintenance Infliximab Therapy to Biosimilar-Infliximab Does Not Lead to Significant Changes in Health-Related Quality of Life and Clinical Outcomes in Inflammatory Bowel Disease Patients

English

Does Infliximab Increase Complications After Surgery for Inflammatory Bowel Disease?

F1000 Medicine Reports

2009

English

Efficacious Transition From Reference Infliximab to Biosimilar Infliximab in Clinical Practice

International Journal of Rheumatic Diseases

Rheumatology

2019

English

Suppression of Anti-Drug Antibodies to Infliximab or Adalimumab With the Addition of an Immunomodulator in Patients With Inflammatory Bowel Disease

Alimentary Pharmacology and Therapeutics

English

Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy

Clinical Gastroenterology and Hepatology

Hepatology

Gastroenterology

2017

English

Letter: Overcoming Secondary Loss of Response to Infliximab-It Is Not the Drug, It Is How You Use It! Authors’ Reply

Alimentary Pharmacology and Therapeutics

English

Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases

Alimentary Pharmacology and Therapeutics

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ioannis Drygiannakis

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Immunological Alterations Mediated by Adenosine During Host-Microbial Interactions

Related publications

Pregnancy Outcomes in Women With Inflammatory Bowel Disease Treated With Biosimilar Infliximab

Letter: Infliximab Therapy for Patients With Inflammatory Bowel Disease - Some Unanswered Questions. Authors’ Reply

Switching Maintenance Infliximab Therapy to Biosimilar-Infliximab Does Not Lead to Significant Changes in Health-Related Quality of Life and Clinical Outcomes in Inflammatory Bowel Disease Patients

Does Infliximab Increase Complications After Surgery for Inflammatory Bowel Disease?

Efficacious Transition From Reference Infliximab to Biosimilar Infliximab in Clinical Practice

Suppression of Anti-Drug Antibodies to Infliximab or Adalimumab With the Addition of an Immunomodulator in Patients With Inflammatory Bowel Disease

Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy

Letter: Overcoming Secondary Loss of Response to Infliximab-It Is Not the Drug, It Is How You Use It! Authors’ Reply

Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases